- Home
- ELBM vs LSTA Comparison
ELBM vs LSTA Comparison
Compare ELBM & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELBM
- LSTA
- Stock Information
- Founded
- ELBM 2011
- LSTA 1980
- Country
- ELBM Canada
- LSTA United States
- Employees
- ELBM N/A
- LSTA N/A
- Industry
- ELBM Industrial Machinery/Components
- LSTA Misc Health and Biotechnology Services
- Sector
- ELBM Miscellaneous
- LSTA Health Care
- Exchange
- ELBM Nasdaq
- LSTA Nasdaq
- Market Cap
- ELBM 22.8M
- LSTA 20.0M
- IPO Year
- ELBM N/A
- LSTA N/A
- Fundamental
- Price
- ELBM $1.05
- LSTA $2.10
- Analyst Decision
- ELBM Strong Buy
- LSTA Strong Buy
- Analyst Count
- ELBM 1
- LSTA 1
- Target Price
- ELBM $2.40
- LSTA $15.00
- AVG Volume (30 Days)
- ELBM 129.0K
- LSTA 10.1K
- Earning Date
- ELBM 05-23-2025
- LSTA 05-08-2025
- Dividend Yield
- ELBM N/A
- LSTA N/A
- EPS Growth
- ELBM N/A
- LSTA N/A
- EPS
- ELBM N/A
- LSTA N/A
- Revenue
- ELBM N/A
- LSTA $1,000,000.00
- Revenue This Year
- ELBM N/A
- LSTA N/A
- Revenue Next Year
- ELBM N/A
- LSTA N/A
- P/E Ratio
- ELBM N/A
- LSTA N/A
- Revenue Growth
- ELBM N/A
- LSTA N/A
- 52 Week Low
- ELBM $0.91
- LSTA $1.87
- 52 Week High
- ELBM $2.83
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- ELBM 41.14
- LSTA 39.57
- Support Level
- ELBM $1.05
- LSTA $2.30
- Resistance Level
- ELBM $1.14
- LSTA $2.46
- Average True Range (ATR)
- ELBM 0.05
- LSTA 0.16
- MACD
- ELBM 0.01
- LSTA -0.02
- Stochastic Oscillator
- ELBM 22.01
- LSTA 6.25
About ELBM Electra Battery Materials Corporation
Electra Battery Materials Corp is building North America's fully integrated, localized, and environmentally sustainable battery materials park. Electra Battery Materials is an integral part of the North American battery supply chain, providing low-carbon, sustainable, and traceable raw materials for the region's fast growing electric vehicle industry.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.